Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.40 |
| ▸ | AURKA | O14965 | 7/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832249 | 0.83 | PARP1 (0.50) | PARP1BCAT2KEAP1NFE2L2MAP4K4 | |
| SCHEMBL29467366 | 0.83 | PARP1 (0.50) | PARP1BCAT2KEAP1NFE2L2MAP4K4 | |
| SCHEMBL4612903 | 0.83 | PARP1 (0.50) | PARP1BCAT2KEAP1NFE2L2MAP4K4 | |
| SCHEMBL18066326 | 0.83 | GSK3B (0.41) | PARP1BCAT2MAP4K4PIM1PRKACA | |
| SCHEMBL18066324 | 0.81 | PARP1 (0.48) | PARP1BCAT2KEAP1NFE2L2MAP4K4 | |
| SCHEMBL18066303 | 0.77 | PRKCI (0.47) | PARP1MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL16619412 | 0.77 | RPS6KB1 (0.43) | PARP1RPS6KB1AURKAAURKB | |
| SCHEMBL18066310 | 0.77 | PIM1 (0.47) | PARP1MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL18066309 | 0.76 | PIM1 (0.47) | PARP1MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL18066325 | 0.76 | CHRNB2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | claimed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | claimed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | claimed |
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | disclosed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | NTPCR, NT5E, PNP | PARP1 85/4885BCAT2 1208/4885KEAP1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.